CD274 and melanoma: PD-L1 has been FDA approved as a biomarker for use in NSCLC, head and neck squamous cell carcinoma, bladder, breast, cervical and gastric cancer, but though extensively studied in melanoma, it has not been FDA approved for this indication [29, 30].